Active, not recruitingPhase 2NCT04262154

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Dana Rathkopf, MD
Memorial Sloan Kettering Cancer Center
Intervention
Atezolizumab(drug)
Enrollment
28 enrolled
Eligibility
18 years · MALE
Timeline
20202026

Study locations (8)

Collaborators

Genentech, Inc. · Stand Up To Cancer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04262154 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia

← Back to all trials